Gold tier: mechanically validated evidence, with its primary source.
83 evidence items · page 3 / 4
42 monthsThe aromatase inhibitor group exhibited a longer median metastasis-free survival time (42.0 months) compared to the tamoxifen group (30.0 ± 1.4 months) among hormone receptor-positive breast cancer patients at Kenyatta National Hospital.
Kenyacancer du seinobserved 2019 to 2022published 2025Journal of the Egyptian National Cancer InstitutePubMeddocument of 6 observations
Breast cancer is the most common cancer in sub-Saharan Africa.
Kenyacancer du seinpublished 2021Journal of the National Comprehensive Cancer Network : JNCCNeurope_pmcdocument of 5 observations
40 %Aromatase inhibitor-treated patients had a lower mortality rate (40%) compared to tamoxifen-treated patients (48.0%) among hormone receptor-positive breast cancer patients at Kenyatta National Hospital.
Kenyacancer du seinobserved 2019 to 2022published 2025Journal of the Egyptian National Cancer InstitutePubMeddocument of 6 observations
154 casesIn total, 154 cases were included in this study.
Kenyacancer du seinpublished 2024Journal of nuclear medicine : official publication, Society of Nuclear MedicinePubMeddocument of 4 observations
29.7 %Among the 471 participants assessed, the highest proportion had breast cancer (29.7%) and female genital cancers (22.9%).
Kenyacancer du sein · female genital cancerspublished 2017BMC NutritionOpenAlexdocument of 12 observationsDOI 10.1186/s40795-017-0181-z
809 patientsA total of 809 patients with breast cancer were included in the study.
Kenyacancer du seinpublished 2021Journal of the National Comprehensive Cancer Network : JNCCNeurope_pmcdocument of 5 observations
1,813 clinical breast examinationsDuring the pilot in Nyeri County in October-November 2019, 1813 clinical breast examinations were performed.
Kenyacancer du seinobserved October-November 2019published 2022Cancer reports (Hoboken, N.J.)PubMeddocument of 17 observations
57.4 %57.4% of the female breast cancer patients were unemployed.
Kenyacancer du seinpublished 2023Breast cancer research and treatmentPubMeddocument of 7 observations
24 %Aromatase inhibitors showed a lower incidence of disease progression (24%) compared to tamoxifen (29.7%) among hormone receptor-positive breast cancer patients at Kenyatta National Hospital.
Kenyacancer du seinobserved 2019 to 2022published 2025Journal of the Egyptian National Cancer InstitutePubMeddocument of 6 observations
27.9 %In Kenyan women with invasive breast cancer, the mean proportion of leading/invasive edge stroma Tumour Infiltrating Lymphocytes (LE-TILs) was 27.9.
Kenyacancer du seinpublished 2023Breast cancer research and treatmentPubMeddocument of 4 observations
50 %Nearly half of Kenyan women with breast cancer present with advanced disease.
Kenyacancer du seinpublished 2021JCO global oncologyPubMeddocument of 5 observations
27.9 %The prevalence of alcohol consumption as a breast cancer risk factor was 27.9% among the studied women.
Kenyacancer du seinobserved 2019 and 2020published 2026JCO global oncologyPubMeddocument of 10 observations
13.5 %In Kenyan women with invasive breast cancer, the mean proportion of intratumoural stroma Tumour Infiltrating Lymphocytes (sTILs) was 13.5.
Kenyacancer du seinpublished 2023Breast cancer research and treatmentPubMeddocument of 4 observations
39.8 scoreThe mean breast cancer stigma score was 39.8.
Kenyacancer du seinpublished 2025JCO global oncologyPubMeddocument of 5 observations
11 %Mammography equipment utilization increased from 11% to 83% during the pilot in Nyeri County in October-November 2019.
Kenyacancer du seinobserved October-November 2019published 2022Cancer reports (Hoboken, N.J.)PubMeddocument of 17 observations
44 %Breast and cervical cancers accounted for 44% of all cancers in women in Nairobi during 2004–2008.
Kenyacancer du col de l'utérus · cancer du seinobserved 2004-2008published 2015International journal of cancereurope_pmcdocument of 9 observations
24 %Aromatase inhibitors showed a higher rate of complete radiological response (24%) compared to tamoxifen (13.5%) among hormone receptor-positive breast cancer patients at Kenyatta National Hospital.
Kenyacancer du seinobserved 2019 to 2022published 2025Journal of the Egyptian National Cancer InstitutePubMeddocument of 6 observations
50 %Approximately 50% of women with breast cancer admitted to inpatient hospice in Western Kenya voiced worry, depression, and stress.
Kenyacancer du seinobserved 2011-2019published 2022Journal of pain and symptom managementPubMeddocument of 10 observations
84.4 %84.4% of patients who had elevated CA 15-3 levels had disease recurrence on F-FDG PET/CT.
Kenyacancer du seinpublished 2024Journal of nuclear medicine : official publication, Society of Nuclear MedicinePubMeddocument of 4 observations
44 %44% of providers identified four or more of five signs and symptoms of breast cancer.
Kenyacancer du seinpublished 2021JCO global oncologyPubMeddocument of 5 observations
62 patients62 patients had recurrence (positive) on the F-FDG PET/CT scans.
Kenyacancer du seinpublished 2024Journal of nuclear medicine : official publication, Society of Nuclear MedicinePubMeddocument of 4 observations
Colorectal, lung, breast, ovary, corpus uteri and non-Hodgkin lymphoma were more common in Kenyan Asians.
Kenyacancer du sein · colorectal cancer · corpus uteri cancer · lung cancer · non-Hodgkin lymphoma · ovarian cancerpublished 2017International journal of cancereurope_pmcdocument of 7 observationsDOI 10.1002/ijc.30502
6 weeksThe median time from diagnosis to receipt of the initial intervention was 6 weeks.
Kenyacancer du seinpublished 2023Breast cancer research and treatmentPubMeddocument of 7 observations
28.7 %Among cancer outpatients at Kenyatta National Hospital and Texas Cancer Centre, breast cancer accounted for 28.7% of cases and cervical cancer for 23.2% of cases.
Kenyacancer du seinpublished 2018Double Burden of Malnutrition among Cancer Outpatients in Nairobi, Kenya: Challenges and OOpenAlexdocument of 8 observations
70 %Over 70% of women with breast cancer admitted to inpatient hospice in Western Kenya died in hospice.
Kenyacancer du seinobserved 2011-2019published 2022Journal of pain and symptom managementPubMeddocument of 10 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.